Clinical Trials Directory

Trials / Completed

CompletedNCT02949934

Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
90 (actual)
Sponsor
Medical University of South Carolina · Academic / Other
Sex
All
Age
21 Years – 40 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT) inhibitor tolcapone, relative to placebo, reduces alcohol drinking and alcohol cue-elicited brain activation and increases brain activation associated with cognitive control as a function of a participant's genotype at a polymorphism in the COMT gene.

Conditions

Interventions

TypeNameDescription
DRUGTolcapone
DRUGPlacebo

Timeline

Start date
2016-05-01
Primary completion
2021-04-13
Completion
2021-04-13
First posted
2016-10-31
Last updated
2023-06-09
Results posted
2022-04-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02949934. Inclusion in this directory is not an endorsement.